company background image
BIIB logo

Biogen BASE:BIIB Stock Report

Last Price

AR$17.98k

Market Cap

AR$27.0t

7D

-2.3%

1Y

116.2%

Updated

27 Mar, 2024

Data

Company Financials +

BIIB Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

BIIB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Biogen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share PriceUS$17,982.50
52 Week HighUS$26,200.00
52 Week LowUS$8,281.00
Beta-0.024
1 Month Change-4.85%
3 Month Change-4.58%
1 Year Change116.19%
3 Year Change470.87%
5 Year Changen/a
Change since IPO2,256.82%

Recent News & Updates

Recent updates

Shareholder Returns

BIIBAR BiotechsAR Market
7D-2.3%0%0%
1Y116.2%0%0%

Return vs Industry: BIIB exceeded the AR Biotechs industry which returned 2.8% over the past year.

Return vs Market: BIIB underperformed the AR Market which returned 386.9% over the past year.

Price Volatility

Is BIIB's price volatile compared to industry and market?
BIIB volatility
BIIB Average Weekly Movement7.1%
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in AR Market0%
10% least volatile stocks in AR Market0%

Stable Share Price: BIIB's share price has been volatile over the past 3 months.

Volatility Over Time: BIIB's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19787,570Chris Viehbacherhttps://www.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIB fundamental statistics
Market capAR$26.97t
Earnings (TTM)AR$995.93b
Revenue (TTM)AR$8.44t

27.1x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIIB income statement (TTM)
RevenueUS$9.84b
Cost of RevenueUS$2.53b
Gross ProfitUS$7.30b
Other ExpensesUS$6.14b
EarningsUS$1.16b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)7.99
Gross Margin74.24%
Net Profit Margin11.81%
Debt/Equity Ratio46.9%

How did BIIB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.